论文部分内容阅读
急非淋白血病(ANLL)的治疗,国外多用DA或DAT方案,完全缓解率(CR)可达60％～80％国内多用HOAP方案,CR约为40％～60％。近我们曾取ANLL患者骨髓按Minden等描述的祛T细胞法作原代白血病细胞集落体外培养(CFU-L),并进行了三尖杉酯碱(H)与柔红霉素(D)的药敏试验,发现两药在一定范围浓度内,对CFU-L的抑制作用相近,且H的体外药敏结果与临床疗效相吻合.因此,我们采用HA方案(三尖杉酯碱加阿糖胞苷)治疗ANLL,报道如下。
Acute non-leukemia (ANLL) treatment, foreign programs with DA or DAT, complete remission rate (CR) up to 60% ~ 80% domestic multi-purpose HOAP program, CR about 40% to 60%. Nearly all of the bone marrow from patients with ANLL had CFU-L derived from the leukemia cells treated with T cell method described by Minden et al., And had been treated with harringtonine (D) Drug susceptibility test found that the two drugs in a certain range of concentrations, the inhibitory effect of CFU-L is similar, and H in vitro susceptibility results and clinical efficacy consistent.Therefore, we use the HA program (harringtonine plus arabinose Cytidine) for the treatment of ANLL, reported below.